CliffBio
small molecule

ALIQOPA

COPANLISIB DIHYDROCHLORIDE

Loss of exclusivityMarch 2032latest FDA-listed patent expiry
CompanyBayer Healthcare →See this company's full patent-cliff portfolio

Drug detail

Brand nameALIQOPA
Active ingredientCOPANLISIB DIHYDROCHLORIDE
Strength60MG/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalSeptember 2017
Marketing statusDISCN

Listed patents

PatentExpiresType
9636344March 2032use U-2124
10383876March 2032substance, product
RE46856October 2029substance, product

More from Bayer Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.